| CAS NO: | 887375-15-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 887375-15-7 |
| 别名 | (S)-ZK-245186; (S)-BOL-303242X |
| Canonical SMILES | CC(C)(C1=C(OCC2)C2=CC(F)=C1)C[C@](O)(CNC3=C4C=CC(C)=NC4=CC=C3)C(F)(F)F |
| 分子式 | C25H26F4N2O2 |
| 分子量 | 462.48 |
| 溶解度 | DMSO: ≥ 50.6 mg/mL (109.41 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | (S)-Mapracorat is a selective and less active glucocorticoid receptor agonist. (S)-Mapracorat concentration dependently inhibited TNFα secretion from activated canine PBMC with IC50 value of approximately 0.2 nM. Intradermal injection of compound 48/80 (50 μg in 50 μL saline) resulted in a clear wheal and flare reaction over the 60 min observation period. Topical pre-treatment with (S)-Mapracorat (0.1%) leads to significant reduction in the wheal and flare responses compared to vehicle (acetone) treated areas. [1]. BÄumer W , et al. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Vet Dermatol. 2017 Feb; 28(1):46-e11. |
m.cnreagent.com